Form 4: Heron Therapeutics Executive Exercises Stock Options
SEC Form 4 Filing
William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, exercised stock options and acquired 11,694 shares of common stock on April 30, 2025.
Summary
- On April 30, 2025, William P. Forbes, the EVP and Chief Development Officer of Heron Therapeutics, Inc., executed a transaction involving the company's stock.
- Forbes exercised restricted stock units, acquiring 11,694 shares of common stock.
- Following the transaction, Forbes directly owns 122,566 shares of Heron Therapeutics common stock.
- He also directly owns 175,416 derivative securities in the form of restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of an executive exercising stock options, which doesn't inherently indicate positive or negative sentiment.
Positives
- The exercise of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine insider transaction.
Key Dates
| Date | Description |
|---|---|
| January 31, 2025 | Date of grant for restricted stock units, which vest in 16 equal installments beginning one quarter after this date. |
| April 30, 2025 | Date of transaction: Forbes exercised restricted stock units and acquired common stock. |
| May 02, 2025 | Date of signature for the Form 4 filing. |
Keywords
Heron Therapeutics, HRTX, William P. Forbes, stock options, restricted stock units, Form 4, insider trading, EVP, Chief Development Officer, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.